Progenics Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$20.5M
Doctors Paid
7,322
Transactions
19,531
2024 Total
$4.8M
Payment Breakdown by Category
Research$15.1M (73.6%)
Consulting$1.7M (8.2%)
Food & Beverage$576,493 (2.8%)
Travel$389,244 (1.9%)
Royalty/License$7,700 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $15.1M | 1,375 | 73.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.6M | 891 | 12.5% |
| Consulting Fee | $1.7M | 324 | 8.2% |
| Food and Beverage | $576,493 | 15,989 | 2.8% |
| Travel and Lodging | $389,244 | 903 | 1.9% |
| Space rental or facility fees (teaching hospital only) | $72,100 | 24 | 0.4% |
| Grant | $60,000 | 5 | 0.3% |
| Long term medical supply or device loan | $27,500 | 7 | 0.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $25,530 | 6 | 0.1% |
| Royalty or License | $7,700 | 2 | 0.0% |
| Education | $2,686 | 5 | 0.0% |
Payments by Type
Research
$15.1M
1,374 transactions
General
$5.4M
18,156 transactions
Ownership
$0
1 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Study of 18F DCFPyL PET CT Imaging in Patients With Suspected Recurrence of Prostate Cancer CONDOR | $4.1M | 2 | 116 |
| Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant | $3.4M | 0 | 302 |
| STUDY OF I-131-1095 RADIOTHERAPY IN COMBINATION WITH ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRA | $1.7M | 0 | 115 |
| PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR | $1.4M | 0 | 167 |
| 2-(3-{1-CARBOXY-5-[(6-18F-FLUORO-PYRIDINE-3-CARBONYL)-AMINO]-PENTYL}-UREIDO)-PENTANEDIOIC ACID (PYL) IN PATIENTS WITH HIGH RISK AND BIOCHEMICALLY RECURRENT PROSTATE CANCER | $487,600 | 0 | 106 |
| Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (ARROW) | $469,031 | 0 | 45 |
| AN OBSERVATIONAL STUDY TO ASSESS THE RISK OF SECONDARY MALIGNACIES FOLLOWING TREATMENT WITH AZEDRA | $463,653 | 0 | 18 |
| A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer-MOONSHOT-MGH | $398,912 | 0 | 86 |
| MIP-IB12B-EAP | $239,654 | 0 | 5 |
| MULTIMODAL PET/MRI MACHINE LEARNING APPROACHES FOR CHARACTERIZATION OF PRIMARY PROSTATE CANCER | $172,463 | 0 | 35 |
| [1685514-1] - PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) SCAN AND MULTIPARAMETRIC MRI FOR PROSTATE BIOPSY DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER | $157,771 | 0 | 31 |
| High-Resolution, 18F-PSMA PET-MRI for Mapping Prostate Cancer in Patients Considering Focal High-Intensity Focused Ultrasound (HIFU) Therapy | $155,388 | 0 | 33 |
| A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer-MOONSHOT-MSKCC | $151,800 | 0 | 33 |
| A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer-MOONSHOT-NCI | $145,084 | 0 | 31 |
| PROSTRATE SPECIFIC MEMBRANE ANTIGEN (PSMA) SCAN AND MULTIPARAMETRIC MRI FOR PROSTRASTE BIOPSY DETECTION OF CLINICALLY SIGNIFICANT PROSTRATE CANCER | $128,409 | 0 | 6 |
| A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer-MOONSHOT-MSSKCC | $123,188 | 0 | 26 |
| Phase 3 randomized trial of PSMA PET prior to definitive radiotherapy for intermediate- or high-risk prostate cancer | $110,538 | 0 | 24 |
| Real World Validation of of Deep Learning Algorithms in Assessment of Metastasis in Medical Imaging of Patients with Prostate Cancer | $104,000 | 0 | 1 |
| THE UTILITY OF PSMA PET IMAGING FOR DETECTING EARLY METASTATIC PROSTATE CANCER IN MEN WITH HIGH GC DECIPHER TEST SCORES A SUB AIM OF THE VANDAAM STUDY MCC NO 18523 | $94,008 | 0 | 18 |
| Phase 3 randomized trial of PSMA PET prior to definitive radiation therapy for intermediate- or high-risk prostate cancer | $84,000 | 0 | 9 |
| Impact of PyL PET/CT on Initial and Subsequent Treatment Strategies of Patients with Prostate Cancer (PROSPYL) | $82,800 | 0 | 18 |
| THE UTILITY OF PSMA-PET IMAGING FOR DETECTING EARLY METASTATIC PROSTATE CANCER IN MEN WITH HIGH GC DECIPHER TEST SCORES: A SUB-AIM OF THE VANDAAM STUDY (MCC #18523) | $68,985 | 0 | 14 |
| The utility of PSMA-PET imaging for detecting early metastatic prostate cancer in men with high GC Decipher test scores:A sub-aim of the VANDAAM study (MCC #18523) | $65,504 | 0 | 14 |
| MULTIMODAL PET-MRI MACHINE LEARNING APPROACHES FOR CHARACTERIZATION OF PRIMARY PROSTATE CANCER | $62,672 | 0 | 12 |
| 18F-DCFPyL PET in Men with Prostate cancer, single-arm prospective trial. Phase 2 Study of18F-DCFPYL Positron Emission Tomography (PET) in Men with Newly Diagnosed Progressive or Metastatic Prostate Cancer | $55,200 | 0 | 12 |
| A COMPARATIVE STUDY OF 68GA-PSMA-11 AND 18F-DCFPYL-PSMA PET SCANS IN PATIENTS RECEIVING 177-LU-PSMA-617 THERAPY FOR METASTATIC CASTRATE-RESISTANT PROSTATE CANCER | $50,000 | 0 | 1 |
| A PILOT STUDY TO ASSESS THE CLINICAL UTILITY OF PYLARIFY PET-CT FOR DETECTING METASTASIS IN PANCREATIC CANCER, HEPATOCELLULAR CARCINOMA AND BREAST CANCER | $49,570 | 0 | 10 |
| STUDY OF I-131-1095 RADIOTHERAPY IN COMBINATION WITH ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT | $34,493 | 0 | 7 |
| Serial PSMA PET Imaging in the Assessment of Treatment Response in Patients with Progressive Prostate Cancer | $33,166 | 0 | 7 |
| A PHASE II MULTI-INSTITUTIONAL TRIAL TO EVALUATE PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)-BASED PET IMAGING OF HIGH RISK PROSTATE CANCER-MOONSHOT-NCI | $30,451 | 0 | 6 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. April Teitelbaum, Md, MD | Medical Oncology | San Diego, CA | $558,912 | $0 |
| Dr. Stuart Apfel, Md, MD | Neurology | West Hempstead, NY | $462,869 | $0 |
| Dr. Gary Ulaner, M.d. Ph.d, M.D. PH.D | Diagnostic Radiology | Los Angeles, CA | $351,633 | $0 |
| Dr. Edward Obedian, Md, MD | Radiation Oncology | Oyster Bay, NY | $278,415 | $0 |
| Dr. Steven Rowe, M.d., Ph.d, M.D., PH.D | Nuclear Radiology | Dallas, TX | $277,478 | $0 |
| Medhat Osman, Md, MD | Nuclear Medicine | St Louis, MO | $258,459 | $0 |
| Giuseppe Esposito, Md, MD | Nuclear Imaging & Therapy | Washington, DC | $224,389 | $0 |
| Dr. Hossein Jadvar, M.d, M.D | Nuclear Medicine | Los Angeles, CA | $168,627 | $0 |
| Daniel Appelbaum | Nuclear Radiology | Chicago, IL | $151,095 | $0 |
| Tony Abraham, D.o, D.O | Nuclear Radiology | Port Jefferson Station, NY | $131,662 | $0 |
| Dr. Zachary Klaassen, M.d, M.D | Urology | Augusta, GA | $107,483 | $0 |
| Dr. Steven Finkelstein, Md, MD | Radiation Oncology | Syracuse, NY | $88,783 | $0 |
| Dr. Glen Mcwilliams, M.d, M.D | Urology | Bronx, NY | $85,208 | $0 |
| Dr. Vitaly Margulis, Md, MD | Urology | Dallas, TX | $83,306 | $0 |
| Dr. Thomas Boike, M.d, M.D | Radiation Oncology | Clarkston, MI | $75,968 | $0 |
| David Scheinberg, Md, MD | Medical Oncology | New York, NY | $70,614 | $0 |
| Dr. Ashley Ross | Urology | Chicago, IL | $65,803 | $0 |
| Andrew Stephenson, Md, MD | Urology | Syracuse, NY | $60,608 | $0 |
| Elward Crawford, Md, MD | Urology | San Diego, CA | $57,301 | $0 |
| Dr. Munir Ghesani, M.d, M.D | Nuclear Medicine | Princeton, NJ | $45,760 | $0 |
| Dr. David Albala, M.d, M.D | Urology | Syracuse, NY | $39,440 | $0 |
| Dr. Peter Fried, Md, MD | Radiation Oncology | Fairfield, OH | $37,093 | $0 |
| Dr. James Gray, M.d, M.D | Radiation Oncology | Nashville, TN | $31,248 | $0 |
| Vahan Kassabian, M.d, M.D | Urology | Roswell, GA | $30,869 | $0 |
| Edward Uchio, Md, MD | Urology | Orange, CA | $30,153 | $0 |
Ad
Top Products
- PYLARIFY $9.4M
- AZEDRA $860,997
Associated Products (4)
- PYLARIFY $9.4M
- AZEDRA $860,997
- PYLARIFY AI $27,572
- PyL (fluorine-18-dcfpyl) $25,293
Payment Categories
- Food & Beverage $576,493
- Consulting $1.7M
- Travel & Lodging $389,244
- Research $15.1M
- Royalties $7,700
About Progenics Pharmaceuticals, Inc.
Progenics Pharmaceuticals, Inc. has made $20.5M in payments to 7,322 healthcare providers, recorded across 19,531 transactions in the CMS Open Payments database. In 2024, the company paid $4.8M. The top product by payment volume is PYLARIFY ($9.4M).
Payments were distributed across 128 medical specialties. The top specialty by payment amount is Urology ($1.1M to 2,487 doctors).
Payment categories include: Food & Beverage ($576,493), Consulting ($1.7M), Research ($15.1M), Travel & Lodging ($389,244), Royalties ($7,700).
Progenics Pharmaceuticals, Inc. is associated with 4 products in the CMS Open Payments database, including PYLARIFY, AZEDRA, and PYLARIFY AI.